Comparative Pharmacology
Head-to-head clinical analysis: ORETICYL 25 versus ORETICYL 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORETICYL 25 versus ORETICYL 50.
ORETICYL 25 vs ORETICYL 50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule by binding to the thiazide-sensitive NaCl cotransporter, increasing excretion of sodium, chloride, and water. Deserpidine depletes catecholamines from peripheral sympathetic nerve endings by binding to the vesicular monoamine transporter, reducing vascular resistance and heart rate.
Hydrochlorothiazide inhibits the Na+/Cl- cotransporter in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and increasing diuresis.
Hydrochlorothiazide 25 mg orally once daily; may increase to 50 mg daily if needed.
Hydrochlorothiazide 50 mg orally once daily in the morning; may increase to 100 mg daily in divided doses.
None Documented
None Documented
2.5 hours; in renal impairment may extend to 8–15 hours.
Terminal elimination half-life: 6–15 hours (mean 10 hours), prolonged in renal impairment (up to 24–30 hours) and elderly.
Primarily renal (95% unchanged); minimal biliary (<5%).
Renal: ~95% (50% as unchanged drug, remainder as inactive metabolites); Biliary/fecal: <5%.
Category C
Category C
Diuretic Combination
Diuretic Combination